Filing Flows › Lipocine (LPCN) › Q2 2026 › vs Q2 2025
Lipocine (LPCN) Q2 2026 vs Q2 2025 (year over year)
Lipocine's revenue fell $433K (-69%) from $623K in Q2 2025 to $190K in Q2 2026.
Lipocine, Q2 2026: revenue $190K (-70% year over year), net loss $2.6M, operating cash flow −$3.0M. The chart draws each line against Q2 2025, the increases inside each band.
Every line
| Line | Q2 2026 | Q2 2025 | Change | % |
|---|---|---|---|---|
| Revenue | $190K | $623K | −$433K | -69% |
| Other income, net | $220K | $199K | $21K | +11% |
| Net loss | $2.6M | $2.2M | $417K | +19% |
| Costs & expenses | $3.0M | $3.0M | $5K | +0.2% |
| Operating costs | $3.0M | $3.0M | $5K | +0.2% |
| Income tax | $200 | $0 | $200 | — |
| Research & development | $2.0M | $2.1M | −$95K | -4% |
| General & admin | $991K | $890K | $101K | +11% |
| Operating cash sources | $3.1M | $2.0M | $1.1M | +58% |
| Depreciation & amortization | $15K | $16K | −$1K | -9% |
| Share-based compensation | $58K | $65K | −$7K | -11% |
| Cash used in operations | $3.0M | $1.9M | $1.1M | +61% |
| Net loss absorbed | $2.6M | $2.2M | $417K | +19% |
| Working capital & other | $479K | −$238K | $717K | — |
Questions
How much did Lipocine's revenue grow year over year in Q2 2026?
Lipocine's revenue fell $433K (-69%) from $623K in Q2 2025 to $190K in Q2 2026.